Fluence Analytics is a manufacturer of industrial and laboratory monitoring solutions that produce continuous data streams. The company has two product lines, ACOMP and ARGEN. Combined with powerful, proprietary analytical tools, the confluence of data from our measurements enable realtime optimization leading to improved process control and faster R&D for polymer and biopharmaceutical manufacturers. Visit www.FluenceAnalytics.com to learn more about the company’s solutions for realtime data.
NOvate Medical Technologies, LLC (“NOvate”) is a New Orleans-based medical device development company focused on commercializing low-cost medical products. NOvate’s first product offering, SafeSnip, is aimed at decreasing healthcare costs and increasing standards of care while addressing global health issues.
Theodent was partly founded by prestigious scientists in different but complementary fields and the company was launched in January 2012. The discovery of those scientists sets the stage to finally provide the world an alternative to fluoride based oral care products.
Bioceptive was founded in September 2010 to address the adverse events caused by current insertion tools and techniques as well as to expand access to the IUD worldwide by providing a more intuitive procedure for inserting IUDs. Bioceptive is a venture-backed company in development stage of its patent-pending device and seeks to bring the device through regulatory approval, making available a much needed device to women across the world.
Advano is a full-stack battery company focused on improving the energy density of lithium-ion batteries for electric vehicles, stationary storage, and flexible electronics. The company was founded in 2014 by Alexander Girau (MS 12') and was spun-out of Dr. Brian Mitchell's laboratory in Chemical and Biomolecular Engineering with early technology based on manufacturing of surface fucntionalized silicon nanoparticles. Advano now focuses on a wide-array of 3D silicon-carbon materials, conductive polymers, advanced liquid electrolytes, and cell-build engineering technologies. Advano is venture-backed with funding from Tier 1 VC groups; Silicon Valley's prominent start-up accelerator, Y Combinator; as well as funding from government agencies such as U.S. Department of Energy and Louisiana Board of Regents.
Tympanogen was founded in 2014 by Tulane biomedical engineers passionate about improving healthcare for children. The company's lead product, Perf-Fix, is a gel patch for nonsurgical eardrum repair. Tympanogen is commercializing this proprietary gel material for additional otologic and wound-care applications.
AxoSim Technologies, LLC was founded in 2014 to improve preclinical pharmaceutical development. Using advanced “nerve-on-a-chip” technology, AxoSim’s mission is to facilitate the prediction of neurological safety and efficacy in order to develop the next generation of therapeutics, ultimately improving health and well-being.
Crescentium is a Tulane University medical device startup aimed at providing ICU facilities with safe, inexpensive medical devices for intubated patients. Crescentium's initial entry to market is called the GemView-LM; a modified laryngeal mask designed to increase the quality of care during common ICU procedures such as percutaneous dilatational tracheostomies, difficult airway intubations and laryngeal edema diagnosis.
BioAesthetics is developing an acellular nipple-areolar complex graft for patients who have undergone mastectomies. BioAesthetics's grafts would allow for the patient's own cells to migrate into and repopulate the graft thereby integrating with the patient's body.
Every year, 5 million biopsy procedures are performed to diagnose cancer in the United States. Of those 5 million patients, 1 million need repeat procedures due to inadequate biopsy quality. Repeat procedures can delay life-saving treatments for over 2 months. To address this problem, Instapath has developed a microscopy system for rapid point-of-procedure biopsy evaluation. Instapath ensures the quality of biopsies by providing an exact picture of a whole biopsy at subcellular resolution within seconds of removal. By reducing biopsy procedure time, Instapath also doubles throughput for the hospitals.
